Related Experiment Video
Updated: Dec 20, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells
Souad R Sennoune1, Thomas Nelius1, Courtney Jarvis2
1Department of Urology, Texas Tech University-Health Sciences Center, Lubbock, Texas, United States of America.
Background:
Despite new drugs, metastatic prostate cancer remains fatal. Growing interest in the latest approved cabazitaxel taxane drug has markedly increased due to the survival benefits conferred when used at an earlier stage of the disease, its promising new therapeutic combination and formulation, and its differential toxicity. Still cabazitaxel's mechanisms of resistance are poorly characterized. The goal of this study was thus to generate a new model of acquired resistance against cabazitaxel in order to unravel cabazitaxel's resistance mechanisms.
Methods:
Du145 cells were cultured with increasing concentrations of cabazitaxel, docetaxel/ taxane control or placebo/age-matched control. Once resistance was reached, Epithelial-to-Mesenchymal Translation (EMT) was tested by cell morphology, cell migration, and E/M markers expression profile. Cell transcriptomics were determined by RNA sequencing; related pathways were identified using IPA, PANTHER or KEGG software. The Wnt pathway was analyzed by western blotting, pharmacological and knock-down studies.
Results:
While age-matched Du145 cells were sensitive to both taxane drugs, docetaxel-resistant cells were only resistant to docetaxel and cabazitaxel-resistant cells showed a partial cross-resistance to both drugs concomitant to EMT. Using RNA-sequencing, the Wnt non-canonical pathway was identified as exclusively activated in cabazitaxel resistant cells while the Wnt canonical pathway was restricted to docetaxel-resistant cells. Cabazitaxel-resistant cells showed a minimal crossover in the Wnt-pathway-related genes linked to docetaxel resistance validating our unique model of acquired resistance to cabazitaxel. Pharmacological and western blot studies confirmed these findings and suggest the implication of the Tyrosine kinase Ror2 receptor in cabazitaxel resistant cells. Variation in Ror2 expression level altered the sensitivity of prostate cancer cells to both drugs identifying a possible new target for taxane resistance.
Conclusion:
Our study represents the first demonstration that while Wnt pathway seems to play an important role in taxanes resistance, Wnt effectors responsible for taxane specificity remain un-identified prompting the need for more studies.
Insights
Acquired resistance to cabazitaxel in prostate cancer cells involves the Wnt non-canonical pathway and the Ror2 receptor. Understanding these cabazitaxel resistance mechanisms may reveal new therapeutic targets for metastatic prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Metastatic prostate cancer remains a fatal disease, driving the need for novel therapeutic strategies.
- Cabazitaxel, a taxane drug, shows promise but its resistance mechanisms are poorly understood.
- Investigating cabazitaxel resistance is crucial for improving treatment outcomes in advanced prostate cancer.
Purpose of the Study:
- To develop a new model of acquired cabazitaxel resistance in prostate cancer cells.
- To elucidate the molecular mechanisms underlying cabazitaxel resistance.
- To identify potential therapeutic targets for overcoming taxane resistance.
Main Methods:
- Established cabazitaxel-resistant Du145 prostate cancer cell lines.
- Assessed Epithelial-to-Mesenchymal Transition (EMT) markers and cell migration.
- Utilized RNA sequencing for transcriptomic analysis and pathway identification (IPA, PANTHER, KEGG).
- Investigated Wnt pathway activation via western blotting and knock-down studies.
Main Results:
- Cabazitaxel-resistant cells exhibited partial cross-resistance to docetaxel and displayed EMT.
- RNA sequencing revealed exclusive activation of the Wnt non-canonical pathway in cabazitaxel-resistant cells.
- The Tyrosine kinase Ror2 receptor was implicated in cabazitaxel resistance, with its expression level affecting drug sensitivity.
Conclusions:
- The Wnt pathway plays a significant role in taxane resistance, with distinct canonical and non-canonical pathway activation.
- The Ror2 receptor represents a potential novel target for overcoming cabazitaxel and docetaxel resistance.
- Further research is needed to identify specific Wnt effectors responsible for taxane resistance.
Related Concept Videos
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Intrinsic Apoptotic Pathway

